Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famotidine in pulmonary arterial hypertension
NCT03554291Phase 2Completed
- Sponsor
- University of Washington
- Start
- May 2019
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary arterial hypertension (PAH) and right-sided heart failure comparing Famotidine Arm with Placebo Arm (2 arms). Primary endpoint: Six-minute Walk Distance at 24 weeks. Started May 2019; status: completed.
02
Drugs
famotidine
03
Conditions
pulmonary arterial hypertension (PAH)right-sided heart failure
Beyond the preview
Go deeper on NCT03554291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03554291.